研究

Haeno T, Sakai K, Minamoto S, Nakatsu D, De Velasco MA, Rai S, Tanaka H, Matsumura I, Nishio K.

Clonal Complexity Defines Distinct Tumor-Intrinsic Biology and Prognosis in Diffuse Large B-Cell Lymphoma.

Aoki T, Duns G, Rai S(co-1st), Jiang A, Lytle A, Yin Y, Kishida M, Yu Li M, Lee C, Smorra D, Hilton LK, Healy S, Alig SK, Shahrokh Esfahani M, Sarkozy C, Hung SS, Milne K, Telenius A, O Brien L, Wong JC, Cassidy C, Fujisawa M, Strong C, Goodyear T, Di Vito C, Luksik C, Edin G, Gonzalez L, Rangel Patiño J, Hong M, Wu S, Lee E, Sakhdari A, Takata K, Miyata-Takata T, Boyle M, Ben-Neriah S, Weng AP, Xu A, Merchant A, Roth A, Crump M, Kuruvilla J, Prica A, Kridel R, Huntsman DG, Nelson BH, Farinha P, Morin RD, Alizadeh AA, Savage KJ, Scott DW, Steidl C.

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Yin Y, Rai S(co-1st), Jiang A, Xu A, O'Brien L, Telenius A, Delabie J, Chong L, Hung S, Merchant A, Scott DW, Savage KJ, Aoki T, Steidl C.

Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq

Sehn LH, Hübel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jiménez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M.

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Fujii-Hanamoto A, Tanaka H, Fujimoto K, Haeno T, Miyake Y, Fujiwara R, Kumode T, Serizawa K, Morita Y, Hanamoto H, Rai S, Matsumura I.

Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells

Rai S, Duns G, Frontzek F, Wong JCH, Yin Y, Li MY, Kishida M, Fujisawa M, Healy S, Viganò E, Jiang A, Woolcock B, Telenius A, Ben-Neriah S, Meissner B, Boyle M, Nakamura H, O Brien L, Cassidy C, Lytle A, Farinha P, Slack GW, Hilton LK, Morin RD, Venturutti L, Aoki T, Wretham N, Bush JW, Evgin L, Savage KJ, Scott DW, Steidl C.

Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma

Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K.

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Alig SK, Shahrokh Esfahani M, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, Jin MC, Olsen M, Telenius A, Mutter JA, Schroers-Martin JG, Sworder BJ, Rai S, King DA, Schultz A, Bögeholz J, Su S, Kathuria KR, Liu CL, Kang X, Strohband MJ, Langfitt D, Pobre-Piza KF, Surman S, Tian F, Spina V, Tousseyn T, Buedts L, Hoppe R, Natkunam Y, Fornecker LM, Castellino SM, Advani R, Rossi D, Lynch R, Ghesquières H, Casasnovas O, Kurtz DM, Marks LJ, Link MP, André M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA.

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Rai S, Tanaka H, Suzuki M, Espinoza JL, Kumode T, Tanimura A, Yokota T, Oritani K, Watanabe T, Kanakura Y, Matsumura I.

Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V.